FDA Broadens Emergency Use Authorization of Remdesivir

For the unprecedented COVID-19 several drugs haven suggested as a precautionary through treatment. Novel drugs as well the re-purposing of the drugs is at their high to combat the COVID-19. Drugs like Hydroxychloroquine, anti-viral agents were indicated for its treatment. The drug Remdesivir emerged as the finest choice for treatment of the symptoms.
The Gilead’s Remdesivir is an Investigational nucleotide derivative with broad spectrum of anti-viral activity, is being prescribed across the world in its generic forms as well is said to promising against the infections being caused by SARS and MERS. To be mentioned here is that Remdesivir is an experimental medicine and was not provided with safety and efficacy.
Considering the fact of its significant activity against Ebola, the drug Remdesivir is being used most widely as of now for treatment against novel SARS-CoV-2.
On August 28, 2020 the United States Food and Drug Administration has broadened the EUA of Remdesivir for adult and pediatric in-patients irrespective of severity of disease.